# Question 5

**Type:** Treatment

**Question:** What treatment did most patients receive in the MSK-CHORD Study?

**Answer:**

## Answer

Based on the MSK-CHORD study data, the most commonly received treatments were:

**Top 5 Treatment Agents:**

1. **Fluorouracil (5-FU)** - 6,319 patients (29.4%)
2. **Leucovorin** - 5,573 patients (26.0%)
3. **Oxaliplatin** - 5,489 patients (25.6%)
4. **Capecitabine** - 4,808 patients (22.4%)
5. **Carboplatin** - 4,604 patients (21.4%)

**Key Findings:**

- Out of 24,028 patients with treatment data in MSK-CHORD, 21,473 patients have specific treatment agent information recorded
- The top treatments are primarily chemotherapy agents, with **Fluorouracil** being the most common, received by nearly 30% of patients
- The combination of Fluorouracil, Leucovorin, and Oxaliplatin (often given together as the FOLFOX regimen) appears frequently, which is a standard chemotherapy protocol for colorectal and other gastrointestinal cancers
- Other common treatments include:
  - **Irinotecan** (4,329 patients, 20.2%)
  - **Gemcitabine** (4,038 patients, 18.8%)
  - **Paclitaxel** (3,679 patients, 17.1%)
  - **Pemetrexed** (3,357 patients, 15.6%)

The treatment patterns reflect the diverse cancer types included in the MSK-CHORD study, with a strong representation of chemotherapy regimens commonly used for solid tumors.

---

## Model Information
**Model:** anthropic:claude-sonnet-4-5-20250929
**Provider:** Anthropic
**Max Tokens:** 4096

---

*Generated on 2026-02-03 16:03:42*